Cronobacter sakazakii

Reckitt Recalls Two Batches of ProSobee 12.9 oz Simply Plant-Based Infant Formula Because of Possible Health Risk

Retrieved on: 
Monday, February 20, 2023
Women, Parenting, Other Retail, Baby, Maternity, Fitness & Nutrition, Supermarket, Food, Beverage, Consumer, Health, Retail, Cronobacter, World Health Organization, Safety, Infant, Parent, Cronobacter sakazakii, Bacteria, Universal Product Code, Multimedia, Infant formula, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dietary supplement, Reckitt

Simply Plant-Based Infant Formula due to a possibility of cross-contamination with Cronobacter sakazakii.

Key Points: 
  • Simply Plant-Based Infant Formula due to a possibility of cross-contamination with Cronobacter sakazakii.
  • No other ProSobee Simply Plant-Based Infant Formula batches or other Reckitt products are impacted.
  • It is for this reason that we have the highest level of confidence in the safety and quality of every infant formula we make.
  • Consumers who purchased ProSobee Simply Plant-Based Infant Formula should check the bottom of the can to identify whether the batch number is affected.

2022 in Press Releases: The Year's Must-Read Stories

Retrieved on: 
Friday, December 30, 2022
Online, Sony, OTC, Related, Travel, Bank, PR Newswire, Hearing aid, Rest, FTX, News, Great Lakes, ProfNet, Kool-Aid, Radio, Housing, Financial health management, Macdonald, Face, HARD, FDA, LensCrafters, Eating, Court TV, Great Lakes region, Cronobacter, MTN, Hibernation, Parler, Subject-matter expert, Bank of America, Weather, Cronobacter sakazakii, Multimedia, Parent, Database, Extreme, Sale, Acquisition, Hospital, Internet, Social media, Ye, LendingClub, Transport, Heart, Capital Dynamics (global asset manager), DeLorean, EBay, Happy Meal, Walmart, Publication, Musk, Emotion, Mental health, Farmer, Legislation, Geography, Publishing, Video game console, Cryptocurrency

NEW YORK, Dec. 30, 2022 /PRNewswire/ -- With more than 300,000 press releases hitting the wire this year, it was difficult to keep up with everything on PR Newswire. As another year at the wire comes to an end, the team is recapping some major stories from 2022 that couldn't be missed.

Key Points: 
  • As another year at the wire comes to an end, the team is recapping some major stories from 2022 that couldn't be missed.
  • Some strayed from the more "traditional" press release format to focus on storytelling and appeal to readers' emotions.
  • Click on the press release headlines to access the full story and accompanying multimedia assets that are available for download.
  • PR Newswire thoroughly researches and vets this community to verify their identity as a member of the press, blogger or influencer.

Abbott Investors: Please Contact the Portnoy Law Firm to Recover Your Losses; Last Days to Actively Participate in the Case; October 31, 2022

Retrieved on: 
Thursday, October 27, 2022
Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Safety, OSHA, Risk, Similac, Bacteria, Food, Abbott Laboratories, Complaint, News, GLOBE, Review, FDA, Lists of schools in England, Infant, NYSE, Cronobacter sakazakii, United, Life insurance, Risk management, Pharmaceutical industry, Cronobacter

Abbott investors with over $500,000 in losses on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • Abbott investors with over $500,000 in losses on their investment are encouraged to contact Lesley Portnoy, Esq.
  • Please contact attorney Lesley F. Portnoy ,by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • By early 2022, Abbott was responsible for producing 40 percent of the United States infant formula.

ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (NYSE: ABT)

Retrieved on: 
Tuesday, October 25, 2022
Company, Similac, Labour government, Laboratory, NYSE, Death, District court, GLOBE, NEW, FDA, Infant, Investment, Securities Exchange Act of 1934, Bacteria, Cronobacter sakazakii, News, Food and Drug Administration, United, The Legal 500, Advertising, Court, Safety, Fine chemical, Online gambling, Medical device, Cronobacter, Abbott Laboratories

NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Abbott Laboratories (“Abbott” or the “Company”) (NYSE ABT) between February 19, 2021, and June 8, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Abbott Laboratories Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Abbott provides a broad line of health care products, including various forms of infant formula such as Similac, Alimentum and EleCare.
  • Of that amount, approximately 40% of Abbotts formula was produced in its manufacturing facility in Sturgis, Michigan (Sturgis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Abbott Investors: Please contact the Portnoy Law Firm to recover your losses; Last day to actively participate in the case; October 31, 2022

Retrieved on: 
Wednesday, October 19, 2022
News, Risk, Cronobacter sakazakii, Review, Abbott Laboratories, Infant, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, OSHA, Food, Company, United, Lists of schools in England, Safety, Bacteria, Complaint, GLOBE, Similac, Death, FDA, Risk management, Pharmaceutical industry, Cronobacter

Abbott investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • Abbott investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • By early 2022, Abbott was responsible for producing 40 percent of the United States infant formula.
  • As a result of Defendants misrepresentations and omissions, Abbott common stock traded at artificially inflated prices during the Class Period.

ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (NYSE: ABT)

Retrieved on: 
Tuesday, October 18, 2022
News, Laboratory, Cronobacter sakazakii, Advertising, Infant, NYSE, Securities Exchange Act of 1934, Food and Drug Administration, Labour government, Court, Investment, Company, NEW, District court, United, Safety, Bacteria, GLOBE, Similac, Death, The Legal 500, FDA, Fine chemical, Online gambling, Medical device, Abbott Laboratories, Cronobacter

NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Abbott Laboratories (“Abbott” or the “Company”) (NYSE ABT) between February 19, 2021, and June 8, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Abbott Laboratories Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Abbott provides a broad line of health care products, including various forms of infant formula such as Similac, Alimentum and EleCare.
  • Of that amount, approximately 40% of Abbotts formula was produced in its manufacturing facility in Sturgis, Michigan (Sturgis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (NYSE: ABT)

Retrieved on: 
Tuesday, October 11, 2022
News, Laboratory, Cronobacter sakazakii, Advertising, Infant, NYSE, Securities Exchange Act of 1934, Food and Drug Administration, Labour government, Court, Investment, Company, NEW, District court, United, Safety, Bacteria, GLOBE, Similac, Death, The Legal 500, FDA, Fine chemical, Online gambling, Medical device, Abbott Laboratories, Cronobacter

NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Abbott Laboratories (“Abbott” or the “Company”) (NYSE ABT) between February 19, 2021, and June 8, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Abbott Laboratories Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Abbott provides a broad line of health care products, including various forms of infant formula such as Similac, Alimentum and EleCare.
  • Of that amount, approximately 40% of Abbotts formula was produced in its manufacturing facility in Sturgis, Michigan (Sturgis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (NYSE: ABT)

Retrieved on: 
Tuesday, October 4, 2022
Securities Exchange Act of 1934, Court, News, Labour government, United, The Legal 500, Company, FDA, Death, Bacteria, Laboratory, Food and Drug Administration, Safety, District court, NYSE, Similac, Cronobacter sakazakii, Investment, NEW, Infant, Advertising, GLOBE, Fine chemical, Online gambling, Medical device, Abbott Laboratories, Cronobacter

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT) between February 19, 2021, and June 8, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Abbott Laboratories Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Abbott provides a broad line of health care products, including various forms of infant formula such as Similac, Alimentum and EleCare.
  • Of that amount, approximately 40% of Abbotts formula was produced in its manufacturing facility in Sturgis, Michigan (Sturgis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (NYSE: ABT)

Retrieved on: 
Tuesday, September 27, 2022
Securities Exchange Act of 1934, Safety, Advertising, NYSE, FDA, Food, Infant, NEW, United, Similac, News, Investment, Cronobacter sakazakii, Laboratory, Bacteria, Company, Court, District court, GLOBE, Labour government, Food and Drug Administration, The Legal 500, Death, Fine chemical, Online gambling, Medical device, Cronobacter, Abbott Laboratories

NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Abbott Laboratories (“Abbott” or the “Company”) (NYSE ABT) between February 19, 2021, and June 8, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Abbott Laboratories Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Abbott provides a broad line of health care products, including various forms of infant formula such as Similac, Alimentum and EleCare.
  • Of that amount, approximately 40% of Abbotts formula was produced in its manufacturing facility in Sturgis, Michigan (Sturgis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Abbott Laboratories (NYSE: ABT)

Retrieved on: 
Monday, September 19, 2022
Securities Exchange Act of 1934, Safety, Advertising, NYSE, FDA, Food and Drug Administration, Infant, NEW, United, Similac, News, Investment, Cronobacter sakazakii, Laboratory, Bacteria, Company, Court, District court, GLOBE, Labour government, The Legal 500, Death, Fine chemical, Online gambling, Medical device, Cronobacter, Abbott Laboratories

NEW YORK, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT) between February 19, 2021, and June 8, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of Illinois and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Abbott Laboratories Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Abbott provides a broad line of health care products, including various forms of infant formula such as Similac, Alimentum and EleCare.
  • Of that amount, approximately 40% of Abbotts formula was produced in its manufacturing facility in Sturgis, Michigan (Sturgis).
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.